TBXT and hepatocellular carcinoma: In patients with HBV-associated HCC, chimeric antigen receptor T-cells (CAR-T) and T-cell receptor-engineered T-cells targeting HBV antigens have shown antiviral and anti-HCC activities in vitro (137, 138).